Abstract:Chronic obstructive pulmonary disease (COPD) is a pulmonary ailment that is both degenerative and incapacitating, with a global prevalence affecting millions. Despite notable progress in treatment methodologies, there is still a critical requirement for innovative therapeutic interventions. The pathogenesis of COPD has recently seen a significant focus on the role of interleukin 17 (IL-17), a pro-inflammatory cytokine. This review investigates the potential of IL-17 targeting as a viable therapeutic approach for treating COPD. The literature indicates a complex correlation between IL-17 and COPD. Research has indicated that IL-17 plays a role in the manifestation of airway inflammation, remodeling, and mucus hypersecretion, considered characteristic attributes of COPD. Elevated levels of IL-17 have been observed in the lungs of individuals with COPD, indicating its potential as a therapeutic target for intervention. Furthermore, preclinical studies utilizing animal models of COPD have demonstrated the efficacy of anti-IL-17 antibodies in reducing airway inflammation and remodeling. Comprehending the mechanical principles that underlie IL-17 signaling in COPD is imperative for advancing focused, therapeutic interventions. Activating diverse signaling pathways, such as the β-catenin and Act 1 adaptor protein (ACT 1) mediated pathways, is a crucial aspect of COPD pathogenesis triggered by IL-17. As a result, the suppression of IL-17 signaling has exhibited encouraging outcomes in mitigating pulmonary hypertension induced by hypoxia and interrupting the signaling mediated by ACT 1. Notwithstanding these promising discoveries, additional investigation is required to comprehensively explain the function of IL-17 in COPD and its viability as a target for therapy. The efficacy and safety of biological treatments that target IL-17 in COPD patients necessitate thorough investigation despite their initial positive outcomes. Furthermore, identifying appropriate patient subpopulations that would benefit most from IL-17-targeted therapies and optimizing treatment protocols are binding domains for future investigation. The current review presents a persuasive case for the imperative requirement of an additional investigation into the targeting of IL-17 for COPD management. Through a comprehensive analysis of the complex relationship between IL-17 and COPD pathogenesis, novel therapeutic avenues can be explored, potentially transforming the approach to managing this incapacitating condition. As we explore this novel domain, the possibility of pioneering therapies aimed at IL-17 presents a ray of optimism for the multitudes of individuals afflicted with the onerous consequences of COPD.

Th17/Treg Imbalance in Chronic Obstructive Pulmonary Disease: Clinical and Experimental Evidence

Role of Th17 cells, Treg cells, and Th17/Treg imbalance in immune homeostasis disorders in patients with chronic obstructive pulmonary disease

Th17/Treg imbalance in COPD development: suppressors of cytokine signaling and signal transducers and activators of transcription proteins

Imbalance of Peripheral Blood Th17 and Treg Responses in Patients with Chronic Obstructive Pulmonary Disease

Th17/Treg Imbalance: Implications in Lung Inflammatory Diseases

Imbalance of Th17 Cells and Regulatory T Cells in Tuberculous Pleural Effusion.

Imbalance Between Subpopulations of Regulatory T Cells in Copd

Role of Th17/IL-17A in Chronic Inflammatory Airway Diseases

Imbalance of Th17/Treg Cells in Mice with Chronic Cigarette Smoke Exposure.

T-Helper 17 Cell/Regulatory T-Cell Imbalance in COPD Combined with T2DM Patients

The expression and imbalance of Th17 and Treg in peripheral blood of patients with stable chronic obstructive pulmonary disease

Th17 Cells and Its Role in Chronic Obstructive Pulmonary Disease

Change and Significance of Regulatory T Cell and Th17 Cell in Different Stage of Chronic Obstructive Pulmonary Disease

Th1/Th17 Cytokine Profiles Are Associated With Disease Severity And Exacerbation Frequency In Copd Patients

Role of Regulatory T Cells in Disturbed Immune Homeostasis in Patients with Chronic Obstructive Pulmonary Disease

Peripheral Tc17 and Tc17/Interferon-γ Cells are Increased and Associated with Lung Function in Patients with Chronic Obstructive Pulmonary Disease.

The expression and function of TH17 cells in chronic obstructive pulmonary disease

Cd8 Positive T Cells Express Il-17 in Patients with Chronic Obstructive Pulmonary Disease

Unleashing the Power of IL-17: A Promising Frontier in Chronic Obstructive Pulmonary Disease (COPD) Treatment

Research Situation Between Th17 Cells and Chronic Obstructive Pulmonary Disease

Severity of COPD and its relationship with IL-10